Reports
Sale
Chemotherapy Induced Neutropenia Market Share, Forecast: By Drug Type: Colony-Stimulating Factors (CSFs), Granulocyte Colony-Stimulating Factor (G-CSF), Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF); By Application; By Distribution Channel; By End User; Regional Analysis; Supplier Landscape; 2024-2032
Chemotherapy Induced Neutropenia Market Outlook
The chemotherapy induced neutropenia market size is expected to grow at a CAGR of 4.3% during the forecast period of 2024-2032, driven by the rising prevalence of cancer along with the growing demand for effective neutropenia management solutions across the 8 major markets.
Chemotherapy Induced Neutropenia Market Overview
Chemotherapy is the treatment modality that is used to treat different types of cancers. Chemotherapy induced neutropenia is a common risk associated with cancer treatment where neutrophils (a type of white blood cells) have abnormally low counts, making patients susceptible to infections. The market is experiencing a rise in the volume of cancer patients receiving chemotherapy, with over 1 million people in the United States undergoing the treatment annually. Consequently, it is projected to fuel the chemotherapy induced neutropenia demand in the forecast period.
The surge in the approval of treatment products by the health authorities is poised to support the market expansion. In November 2023 , Evive Biotech (a subsidiary of Yifan Pharmaceutical Co., Ltd.) and Acrotech Biopharma (a wholly owned subsidiary of Aurobindo Pharma USA, Inc.) announced the approval of Efbemalenograstim alfa, marketed under the brand name Ryzneuta, by the United States Food and Drug Administration (FDA) to treat chemotherapy induced neutropenia in adult patients with non-myeloid malignancies. The medication developed by Evive Biotech is the first innovative biologics proven to stimulate the production of neutrophils. Acrotech Biopharma will be responsible for the commercialization of the product in the United States. The penetration of such effective treatment options is anticipated to boost the chemotherapy induced neutropenia market growth.
The market is also driven by the increased acquisition and merger initiatives by the key market players to meet the clinical needs of the patients suffering from chemotherapy induced neutropenia. Moreover, the rising patient awareness and the advancement in the healthcare system will accelerate the market value in coming years.
Chemotherapy Induced Neutropenia Market Trends
| Key Trends | Description |
| Advancements in Granulocyte Colony-Stimulating Factor (G-CSF) Therapies | Recent advancements in G-CSF therapies include the development of longer-acting formulations and biosimilars, which offer patient convenience and potentially lower costs of treatment. |
| Increased Focus on Prophylactic Treatments | There is a growing focus on the prophylactic administration of neutropenia management drugs to prevent the onset of neutropenia and its complications, rather than treating it after it occurs. |
| Development of Personalized and Precision Medicine | The field of personalized medicine is influencing the market by offering tailored neutropenia management strategies based on individual patient risk factors, genetic predispositions, and specific chemotherapy regimens. |
| Integration of Predictive Analytics and Artificial Intelligence in Patient Monitoring | Technological advancements in predictive analytics and artificial intelligence (AI) are being explored for their potential to predict the risk and onset of neutropenia in chemotherapy patients. Such technologies could lead to earlier interventions and more precise management of neutropenia. |
Chemotherapy Induced Neutropenia Market Segmentation
Market Breakup by Drug Type
- Colony-Stimulating Factors (CSFs)
- Granulocyte Colony-Stimulating Factor (G-CSF)
- Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
Based on drug types, the market is segmented into colony-stimulating factors (CSFs), granulocyte colony-stimulating factor (G-CSF), and granulocyte-macrophage colony-stimulating factor (GM-CSF). These drugs stimulate the production of white blood cells to prevent or treat neutropenia.
Market Breakup by Application
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Ovarian Cancer
- Others
The chemotherapy induced neutropenia market report includes segmentation based on application as well. It includes breast cancer, lung cancer, colorectal cancer, ovarian cancer, and others. This market segment represents different types of cancers for which chemotherapy induced neutropenia treatments are utilized to manage or prevent complications.
Market Breakup by Distribution Channel
- Online Pharmacies
- Retail Pharmacies
- Hospital Pharmacies
- Others
Distribution channels in the market are online pharmacies, retail pharmacies, hospital pharmacies, and others. The robust network of these channels caters to the diverse needs of the patients and contributes to the chemotherapy induced neutropenia market share.
Market Breakup by End User
- Cancer Research Institutes
- Hospitals
- Clinics
- Others
End users of the market are cancer research institutes, hospitals, clinics, and other healthcare facilities.
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- China
Based on the region, the market includes the United States, EU-4 (Germany, France, Italy, Spain), United Kingdom, Japan, and China. North America dominates the market share which can be attributed to the high prevalence and incidence rates of cancer in the region. Furthermore, the presence of a well-established healthcare system also supports market growth in the market.
Chemotherapy Induced Neutropenia Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Novartis AG
- Lupin Limited
- Ligand Pharmaceuticals
- Biogenomics Limited
- Baxter International
- Apotex
- Evive Biotech
- BeyondSpring Pharmaceuticals
- Myelo therapeutics
- Cellerant Therapeutics
- Aileron Therapeutics
- Enzychem Lifesciences Corporation
- Spectrum Pharmaceuticals
- G1 Therapeutics
- Teva B.V
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Type |
|
| Breakup by Application |
|
| Breakup by Distribution Channel |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Key Queries Solved in the Chemotherapy Induced Neutropenia Market Report
- How has the chemotherapy induced neutropenia market performed so far and how will it perform in the coming years?
- What are the major market trends influencing the market?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- How does the prevalence and incidence of cancer affect the market landscape?
- How does the rising volume of chemotherapy treatments impact the chemotherapy induced neutropenia market value?
- Which drug type of chemotherapy induced neutropenia will dominate the market share?
- Which application is expected to have a high market value in the coming years?
- Which end user will contribute significantly to the market segment?
- How will the ongoing clinical trials impact the market value during the forecast period?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, and mergers & acquisitions among the key market players shaping the market dynamics?
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Chemotherapy Induced Neutropenia Market Overview – 8 Major Markets
3.1 Chemotherapy Induced Neutropenia Market Historical Value (2017-2023)
3.2 Chemotherapy Induced Neutropenia Market Forecast Value (2024-2032)
4 Chemotherapy Induced Neutropenia Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Therapy Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Therapy Success Rate
6 Chemotherapy Induced Neutropenia Epidemiology Analysis-8 Major Markets
6.1 8MM Epidemiology Scenario Overview (2017-2032)
6.2 United States Chemotherapy Induced Neutropenia Epidemiology Scenario and Forecast (2017-2032)
6.3 EU-4 and United Kingdom Chemotherapy Induced Neutropenia Epidemiology Scenario and Forecast (2017-2032)
6.3.1 Germany Chemotherapy Induced Neutropenia Epidemiology Scenario and Forecast (2017-2032)
6.3.2 France Chemotherapy Induced Neutropenia Epidemiology Scenario and Forecast (2017-2032)
6.3.3 Italy Chemotherapy Induced Neutropenia Epidemiology Scenario and Forecast (2017-2032)
6.3.4 Spain Chemotherapy Induced Neutropenia Epidemiology Scenario and Forecast (2017-2032)
6.3.5 United Kingdom Chemotherapy Induced Neutropenia Epidemiology Scenario and Forecast (2017-2032)
6.4 Japan Chemotherapy Induced Neutropenia Epidemiology Scenario and Forecast (2017-2032)
6.5 China Chemotherapy Induced Neutropenia Epidemiology Scenario and Forecast (2017-2032)
7 Chemotherapy Induced Neutropenia Market Landscape*- 8 Major Markets
7.1 Chemotherapy Induced Neutropenia Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Chemotherapy Induced Neutropenia Product Landscape
7.2.1 Analysis by Drug Type
7.2.2 Analysis by Application
8 Chemotherapy Induced Neutropenia Treatment Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Chemotherapy Induced Neutropenia Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.2.1 Strengths
10.2.2 Weaknesses
10.2.3 Opportunities
10.2.4 Threats
10.3 Porter’s Five Forces Model
10.3.1 Bargaining Power of Suppliers
10.3.2 Bargaining Power of Buyers
10.3.3 Threat of New Entrants
10.3.4 Threat of Substitutes
10.3.5 Degree of Rivalry
10.4 Porter’s Five Forces Model
10.5 Key Demand Indicators
10.6 Key Price Indicators
10.7 Industry Events, Initiatives, and Trends
10.8 Value Chain Analysis
11 Chemotherapy Induced Neutropenia Market Segmentation (2017-2032) - 8 Major Markets
11.1 Chemotherapy Induced Neutropenia Market (2017-2032) by Drug Type
11.1.1 Market Overview
11.1.2 Colony-Stimulating Factors (CSFs)
11.1.3 Granulocyte Colony-Stimulating Factor (G-CSF)
11.1.4 Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
11.2 Chemotherapy Induced Neutropenia Market (2017-2032) by Application
11.2.1 Market Overview
11.2.2 Breast Cancer
11.2.3 Lung Cancer
11.2.4 Colorectal Cancer
11.2.5 Ovarian Cancer
11.2.6 Others
11.3 Chemotherapy Induced Neutropenia Market (2017-2032) by Distribution Channel
11.3.1 Market Overview
11.3.2 Online Pharmacies
11.3.3 Retail Pharmacies
11.3.4 Hospital Pharmacies
11.3.5 Others
11.4 Chemotherapy Induced Neutropenia Market (2017-2032) by End User
11.4.1 Market Overview
11.4.2 Cancer Research Institutes
11.4.3 Hospitals
11.4.4 Clinics
11.4.5 Others
11.5 Chemotherapy Induced Neutropenia Market (2017-2032) by Region
11.5.1 Market Overview
11.5.2 United States
11.5.3 EU-4 and the United Kingdom
11.5.3.1 Germany
11.5.3.2 France
11.5.3.3 Italy
11.5.3.4 Spain
11.5.3.5 United Kingdom
11.5.4 Japan
11.5.5 China
12 United States Chemotherapy Induced Neutropenia Market (2017-2032)
12.1 United States Chemotherapy Induced Neutropenia Market Historical Value (2017-2023)
12.2 United States Chemotherapy Induced Neutropenia Market Forecast Value (2024-2032)
12.3 United States Chemotherapy Induced Neutropenia Market (2017-2032) by Drug Type
12.3.1 Market Overview
12.3.2 Colony-Stimulating Factors (CSFs)
12.3.3 Granulocyte Colony-Stimulating Factor (G-CSF)
12.3.4 Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
12.4 United States Chemotherapy Induced Neutropenia Market (2017-2032) by Application
12.4.1 Market Overview
12.4.2 Breast Cancer
12.4.3 Lung Cancer
12.4.4 Colorectal Cancer
12.4.5 Ovarian Cancer
12.4.6 Others
13 EU-4 and United Kingdom Chemotherapy Induced Neutropenia Market (2017-2032)
13.1 EU-4 and United Kingdom Chemotherapy Induced Neutropenia Market Historical Value (2017-2023)
13.2 EU-4 and United Kingdom Chemotherapy Induced Neutropenia Market Forecast Value (2024-2032)
13.3 EU-4 and United Kingdom Chemotherapy Induced Neutropenia Market (2017-2032) by Drug Type
13.3.1 Market Overview
13.3.2 Colony-Stimulating Factors (CSFs)
13.3.3 Granulocyte Colony-Stimulating Factor (G-CSF)
13.3.4 Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
13.4 EU-4 and United Kingdom Chemotherapy Induced Neutropenia Market (2017-2032) by Application
13.4.1 Market Overview
13.4.2 Breast Cancer
13.4.3 Lung Cancer
13.4.4 Colorectal Cancer
13.4.5 Ovarian Cancer
13.4.6 Others
14 Japan Chemotherapy Induced Neutropenia Market (2017-2032)
14.1 Japan Chemotherapy Induced Neutropenia Market Historical Value (2017-2023)
14.2 Japan Chemotherapy Induced Neutropenia Market Forecast Value (2024-2032)
14.3 Japan Chemotherapy Induced Neutropenia Market (2017-2032) by Drug Type
14.3.1 Market Overview
14.3.2 Colony-Stimulating Factors (CSFs)
14.3.3 Granulocyte Colony-Stimulating Factor (G-CSF)
14.3.4 Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
14.4 Japan Chemotherapy Induced Neutropenia Market (2017-2032) by Application
14.4.1 Market Overview
14.4.2 Breast Cancer
14.4.3 Lung Cancer
14.4.4 Colorectal Cancer
14.4.5 Ovarian Cancer
14.4.6 Others
15 China Chemotherapy Induced Neutropenia Market (2017-2032)
15.1 China Chemotherapy Induced Neutropenia Market Historical Value (2017-2023)
15.2 China Chemotherapy Induced Neutropenia Market Forecast Value (2024-2032)
15.3 China Chemotherapy Induced Neutropenia Market (2017-2032) by Drug Type
15.3.1 Market Overview
15.3.2 Colony-Stimulating Factors (CSFs)
15.3.3 Granulocyte Colony-Stimulating Factor (G-CSF)
15.3.4 Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
15.4 China Chemotherapy Induced Neutropenia Market (2017-2032) by Application
15.4.1 Market Overview
15.4.2 Breast Cancer
15.4.3 Lung Cancer
15.4.4 Colorectal Cancer
15.4.5 Ovarian Cancer
15.4.6 Others
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 Japan PMDA
16.1.4 Others
17 Patent Analysis
17.1 Analysis by Type of Patent
17.2 Analysis by Publication Year
17.3 Analysis by Issuing Authority
17.4 Analysis by Patent Age
17.5 Analysis by CPC Analysis
17.6 Analysis by Patent Valuation
17.7 Analysis by Key Players
18 Grants Analysis
18.1 Analysis by Year
18.2 Analysis by Amount Awarded
18.3 Analysis by Issuing Authority
18.4 Analysis by Grant Application
18.5 Analysis by Funding Institute
18.6 Analysis by NIH Departments
18.7 Analysis by Recipient Organization
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Funding Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Partnership and Collaborations Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Supplier Landscape
22.1 Novartis AG
22.1.1 Financial Analysis
22.1.2 Product Portfolio
22.1.3 Demographic Reach and Achievements
22.1.4 Mergers and Acquisition
22.1.5 Certifications
22.2 Lupin Limited
22.2.1 Financial Analysis
22.2.2 Product Portfolio
22.2.3 Demographic Reach and Achievements
22.2.4 Mergers and Acquisition
22.2.5 Certifications
22.3 Ligand Pharmaceuticals
22.3.1 Financial Analysis
22.3.2 Product Portfolio
22.3.3 Demographic Reach and Achievements
22.3.4 Mergers and Acquisition
22.3.5 Certifications
22.4 Biogenomics Limited
22.4.1 Financial Analysis
22.4.2 Product Portfolio
22.4.3 Demographic Reach and Achievements
22.4.4 Mergers and Acquisition
22.4.5 Certifications
22.5 Baxter International
22.5.1 Financial Analysis
22.5.2 Product Portfolio
22.5.3 Demographic Reach and Achievements
22.5.4 Mergers and Acquisition
22.5.5 Certifications
22.6 Apotex
22.6.1 Financial Analysis
22.6.2 Product Portfolio
22.6.3 Demographic Reach and Achievements
22.6.4 Mergers and Acquisition
22.6.5 Certifications
22.7 Evive Biotech
22.7.1 Financial Analysis
22.7.2 Product Portfolio
22.7.3 Demographic Reach and Achievements
22.7.4 Mergers and Acquisition
22.7.5 Certifications
22.8 BeyondSpring Pharmaceuticals
22.8.1 Financial Analysis
22.8.2 Product Portfolio
22.8.3 Demographic Reach and Achievements
22.8.4 Mergers and Acquisition
22.8.5 Certifications
22.9 Myelo Therapeutics
22.9.1 Financial Analysis
22.9.2 Product Portfolio
22.9.3 Demographic Reach and Achievements
22.9.4 Mergers and Acquisition
22.9.5 Certifications
22.10 Cellerant Therapeutics
22.10.1 Financial Analysis
22.10.2 Product Portfolio
22.10.3 Demographic Reach and Achievements
22.10.4 Mergers and Acquisition
22.10.5 Certifications
22.11 Aileron Therapeutics
22.11.1 Financial Analysis
22.11.2 Product Portfolio
22.11.3 Demographic Reach and Achievements
22.11.4 Mergers and Acquisition
22.11.5 Certifications
22.12 Enzychem Lifesciences Corporation
22.12.1 Financial Analysis
22.12.2 Product Portfolio
22.12.3 Demographic Reach and Achievements
22.12.4 Mergers and Acquisition
22.12.5 Certifications
22.13 Spectrum Pharmaceuticals
22.13.1 Financial Analysis
22.13.2 Product Portfolio
22.13.3 Demographic Reach and Achievements
22.13.4 Mergers and Acquisition
22.13.5 Certifications
22.14 G1 Therapeutics
22.14.1 Financial Analysis
22.14.2 Product Portfolio
22.14.3 Demographic Reach and Achievements
22.14.4 Mergers and Acquisition
22.14.5 Certifications
22.15 Teva B.V
22.15.1 Financial Analysis
22.15.2 Product Portfolio
22.15.3 Demographic Reach and Achievements
22.15.4 Mergers and Acquisition
22.15.5 Certifications
23 Chemotherapy Induced Neutropenia Market - Distribution Model (Additional Insight)
23.1 Overview
23.2 Potential Distributors
23.3 Key Parameters for Distribution Partner Assessment
24 Key Opinion Leaders (KOL) Insights (Additional Insight)
25 Company Competitiveness Analysis (Additional Insight)
25.1 Very Small Companies
25.2 Small Companies
25.3 Mid-Sized Companies
25.4 Large Companies
25.5 Very Large Companies
26 Payment Methods (Additional Insight)
26.1 Government Funded
26.2 Private Insurance
26.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Key Questions Answered in the Report
The market is anticipated to grow at a CAGR of 4.3% during the forecast period of 2024-2032, driven by the rising prevalence of cancer along with the growing demand for effective neutropenia management solutions across the 8 major markets.
The market demand is driven by rising patient awareness and investments to bring advancements in the healthcare system.
One of the significant trends in the market is the surge in the approval of treatment products by the health authorities. In November 2023 , Evive and Acrotech Biopharma announced the approval of Ryzneuta by the United States Food and Drug Administration (FDA) to treat chemotherapy induced neutropenia in adult patients with non-myeloid malignancies.
Based on the drug type, the market is segmented into colony-stimulating factors (CSFs), granulocyte colony-stimulating factor (G-CSF), and granulocyte-macrophage colony-stimulating factor (GM-CSF).
Major end users of the market are cancer research institutes, hospitals, clinics, and other healthcare facilities.
Distribution channels in the market include online pharmacies, retail pharmacies, hospital pharmacies, and others.
The market is segmented by application into breast cancer, lung cancer, colorectal cancer, ovarian cancer, among others.
The major regions of the market include the United States, EU-4 (Germany, France, Italy, Spain), United Kingdom, Japan, and China.
Key players involved in the market are Novartis AG, Lupin Limited, Ligand Pharmaceuticals, Biogenomics Limited, Baxter International, Apotex, Evive Biotech, BeyondSpring Pharmaceuticals, Myelo Therapeutics, Cellerant Therapeutics, Aileron Therapeutics, Enzychem Lifesciences Corporation, Spectrum Pharmaceuticals, G1 Therapeutics, and Teva B.V.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER